- Home
- Industry Reports
- Healthcare
- Pharmaceuticals
- Ophthalmic Drugs Market – Size, Outlook, Trends and Forecast (2024 – 2032)
Ophthalmic drugs are the type of drugs which are used to treat glaucoma, cataract, diabetic retinopathy, and other ophthalmic disorders. Introduction of novel ocular drug delivery approaches in the market has driven the manufacturers to develop innovative therapeutic approaches for the treatment of ophthalmic disorders. According to the American Academy of Ophthalmology, 11.3 million people in the U.S. suffer from age-related macular degeneration (AMD), while approximately 10% of them are inflicted with wet AMD. Such trends in ophthalmic disorders across the globe contribute to the growth of the market.
Ophthalmic Drugs Market Segments Size & Growth:
Ophthalmic Drugs market size is projected to reach approximately $55 billion by the end of 2024 with a CAGR of close to 6.6% from $30.25 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Availability of new drugs and devices, the Huge demographic shift towards the emerging markets and Increase in the cataract population and so on. However, Increasing healthcare costs and an Economic slowdown in developed markets are thereby hampering the market growth.
Ophthalmic Drugs Market Segments Share:
Ophthalmic Drugs Market is categorised into drugs which comprise of Ophthalmic swelling, Mydriasis drugs, Ophthalmic inflammation drugs, Anti-glaucoma drugs and so on. Among the Drugs, Ophthalmic Infection Drugs market segment dominated the Ophthalmic Drugs market in 2018 with about XX% share. By Geography, North America is expected to dominate the Ophthalmic Drugs market, and the growth in the North America economies is mainly attributed because of higher uptake of advanced novel products and techniques, and the high cost of therapies among all regions. The market in North America is expected to become worth US$13.78 billion by 2024.
Ophthalmic Drugs Market Trends:
- Roche’s ophthalmic research programs are mainly focused on addressing the leading causes of blindness, including neovascular age-related macular degeneration (AMD), diabetic macular edema, glaucoma, geographic atrophy secondary to AMD and other retinal diseases.
- EyeGate Pharmaceuticals, Inc., a clinical-stage, speciality pharmaceutical company with two platform technologies for treating diseases and disorders of the eye, today announced that it had been granted U.S. Patent No. 9,820,935, by the U.S. Patent and Trademark Office (USPTO). The patent, titled “Delivery of corticosteroids through iontophoresis,” covers the iontophoretic delivery of a dexamethasone phosphate formulation to a subject’s eye for the treatment of various conditions, including post-operative inflammation and uveitis.
Ophthalmic Drugs Market Research Report:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- The major market players, such as
- Roche
- EyeGate Pharmaceuticals
- Novartis International,Inc.
- CIBA Vision
- Abbott Laboratories
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threat
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation, By Drugs
6.1 Ophthalmic Swelling
6.2 Mydriasis Drugs
6.3 Ophthalmic Lubricants
6.4 Ophthalmic Inflammation Drugs
6.5 Ophthalmic Infection Drugs
6.6 Anti-Glaucoma Drugs
Chapter 7 Market Segmentation, By Geography
7.1 North America
7.1.1 Introduction
7.1.2 United States
7.1.3 Canada
7.1.4 Mexico
7.1.5 Others
7.2 Europe
7.2.1 Introduction
7.2.2 U.K
7.2.3 Spain
7.2.4 Italy
7.2.5 France
7.2.6 Russia
7.2.7 Others
7.3 Asia-Pacific
7.3.1 Introduction
7.3.2 China
7.3.3 India
7.3.4 Japan
7.3.5 Australia & New Zealand
7.3.6 Others
7.4 South America
7.4.1 Introduction
7.4.2 Brazil
7.4.3 Argentina
7.4.4 Others
7.5 The Middle East & Africa
7.5.1 Introduction
7.5.2 South Africa
7.5.3 Others
Chapter 8 Competitive Landscape
8.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
8.2 Market Share Analysis
8.3 Strategies Adopted By Top Companies
Chapter 9 Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
9.1. Roche
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Strategic Initiative
9.2. Pfizer
9.3. Novartis International,Inc.
9.4. Merck & Co,Inc.
9.5. Johnson and Johnson
9.6. GSK
9.7. Gene Signal
9.8. EyeGate Pharmaceuticals
9.9. CIBA Vision
9.10. Bristol-Myers Squibb
9.11. Bausch and Lomb
9.12. Ampio Pharma
9.13. Acucela
9.14. Alcon
9.15. Abbott Laboratories
Chapter 11 Market Estimates and Forecast
11.1 Market Estimates and Forecast 2018-2024(USD Million)
11.1.1 Market Estimation and Forecast by Drugs 2018-2024 (USD Million)
11.1.2 Market Estimates and Forecast by Geography 2018-2024 (USD Million)
Chapter 12 Market Insights
12.1 Insights of Industry Experts
13.2 Analyst Opinion (Market Understanding)
13.3 Investment Opportunities
Chapter 14 Appendix
14.1 List of Tables
14.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Global Report
$2,700.00 – $8,100.00
- EUR: €2,489.86 - €7,469.57
- INR: ₹225,053.86 - ₹675,161.59
- AED: د.إ9,909.00 - د.إ29,727.00
- GBP: £2,133.43 - £6,400.30
Additional information
Report Type | Extensive Report, Miniature report, Snapshot Report |
---|---|
Licence | Single User License, Team License, Corporate License |
Ophthalmic drugs are the type of drugs which are used to treat glaucoma, cataract, diabetic retinopathy, and other ophthalmic disorders. Introduction of novel ocular drug delivery approaches in the market has driven the manufacturers to develop innovative therapeutic approaches for the treatment of ophthalmic disorders. According to the American Academy of Ophthalmology, 11.3 million people in the U.S. suffer from age-related macular degeneration (AMD), while approximately 10% of them are inflicted with wet AMD. Such trends in ophthalmic disorders across the globe contribute to the growth of the market.
Ophthalmic Drugs Market Segments Size & Growth:
Ophthalmic Drugs market size is projected to reach approximately $55 billion by the end of 2024 with a CAGR of close to 6.6% from $30.25 billion in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include Availability of new drugs and devices, the Huge demographic shift towards the emerging markets and Increase in the cataract population and so on. However, Increasing healthcare costs and an Economic slowdown in developed markets are thereby hampering the market growth.
Ophthalmic Drugs Market Segments Share:
Ophthalmic Drugs Market is categorised into drugs which comprise of Ophthalmic swelling, Mydriasis drugs, Ophthalmic inflammation drugs, Anti-glaucoma drugs and so on. Among the Drugs, Ophthalmic Infection Drugs market segment dominated the Ophthalmic Drugs market in 2018 with about XX% share. By Geography, North America is expected to dominate the Ophthalmic Drugs market, and the growth in the North America economies is mainly attributed because of higher uptake of advanced novel products and techniques, and the high cost of therapies among all regions. The market in North America is expected to become worth US$13.78 billion by 2024.
Ophthalmic Drugs Market Trends:
- Roche’s ophthalmic research programs are mainly focused on addressing the leading causes of blindness, including neovascular age-related macular degeneration (AMD), diabetic macular edema, glaucoma, geographic atrophy secondary to AMD and other retinal diseases.
- EyeGate Pharmaceuticals, Inc., a clinical-stage, speciality pharmaceutical company with two platform technologies for treating diseases and disorders of the eye, today announced that it had been granted U.S. Patent No. 9,820,935, by the U.S. Patent and Trademark Office (USPTO). The patent, titled “Delivery of corticosteroids through iontophoresis,” covers the iontophoretic delivery of a dexamethasone phosphate formulation to a subject’s eye for the treatment of various conditions, including post-operative inflammation and uveitis.
Ophthalmic Drugs Market Research Report:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
- Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
- Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
- The major market players, such as
- Roche
- EyeGate Pharmaceuticals
- Novartis International,Inc.
- CIBA Vision
- Abbott Laboratories
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threat
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation, By Drugs
6.1 Ophthalmic Swelling
6.2 Mydriasis Drugs
6.3 Ophthalmic Lubricants
6.4 Ophthalmic Inflammation Drugs
6.5 Ophthalmic Infection Drugs
6.6 Anti-Glaucoma Drugs
Chapter 7 Market Segmentation, By Geography
7.1 North America
7.1.1 Introduction
7.1.2 United States
7.1.3 Canada
7.1.4 Mexico
7.1.5 Others
7.2 Europe
7.2.1 Introduction
7.2.2 U.K
7.2.3 Spain
7.2.4 Italy
7.2.5 France
7.2.6 Russia
7.2.7 Others
7.3 Asia-Pacific
7.3.1 Introduction
7.3.2 China
7.3.3 India
7.3.4 Japan
7.3.5 Australia & New Zealand
7.3.6 Others
7.4 South America
7.4.1 Introduction
7.4.2 Brazil
7.4.3 Argentina
7.4.4 Others
7.5 The Middle East & Africa
7.5.1 Introduction
7.5.2 South Africa
7.5.3 Others
Chapter 8 Competitive Landscape
8.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
8.2 Market Share Analysis
8.3 Strategies Adopted By Top Companies
Chapter 9 Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
9.1. Roche
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Strategic Initiative
9.2. Pfizer
9.3. Novartis International,Inc.
9.4. Merck & Co,Inc.
9.5. Johnson and Johnson
9.6. GSK
9.7. Gene Signal
9.8. EyeGate Pharmaceuticals
9.9. CIBA Vision
9.10. Bristol-Myers Squibb
9.11. Bausch and Lomb
9.12. Ampio Pharma
9.13. Acucela
9.14. Alcon
9.15. Abbott Laboratories
Chapter 11 Market Estimates and Forecast
11.1 Market Estimates and Forecast 2018-2024(USD Million)
11.1.1 Market Estimation and Forecast by Drugs 2018-2024 (USD Million)
11.1.2 Market Estimates and Forecast by Geography 2018-2024 (USD Million)
Chapter 12 Market Insights
12.1 Insights of Industry Experts
13.2 Analyst Opinion (Market Understanding)
13.3 Investment Opportunities
Chapter 14 Appendix
14.1 List of Tables
14.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Our Clientele
Exclusive Benefits
Credibility and Transparency
We actively recruit consumers, business professionals, and hard-to-reach individuals as members of our research panels, and we build trusted, ongoing relationships with them. Thus we provide the complete list of primary and secondary data sources in the report to maintain the transparency and to assure the credibility.
Exhaustive Coverage
Detailed and extensive coverage in the geography.Survey consultation for brand tracking, concept testing, consumer behaviour, and more, we have you covered with market research services that scale to meet your needs.
Competitive Edge
Our reports cover most recent updates in the market till the date of the purchase. We identify, gather and timely deliver analysis on impact of unprecedented decisions of CXOs in COVID-19 catastrophe on many businesses, their clients and their clients' clients without additional cost.
Golden Opportunities
A comprehensive strategic sieve analysis of the market by our analysts and consultants, aided by AI tools helps us find the non-obvious, golden and emerging opportunities for you to evaluate.
Top-notch Reports Guaranteed
70% of our research is exclusive; no other research firm has the depth and breadth of our research.
Post Purchase Support
Post-purchase support is provided for all our reports, for three months from the date of purchase, where related queries will be answered within 24 business hours over telephone or email.